CSCamilla Lund Søraas

Camilla Lund Søraas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Camilla Lund Søraas has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PATIENT PROFILING AND OUTCOME OF ANTIHYPERTENSIVE TREATMENT. An Exploratory Analysis of the VALUE Trial

    by Peter W de Leeuw, Camilla L Søraas, Giuseppe Mancia, Maria H Mehlum, Kenneth Jamerson, Solko W Schalm, Sverre E Kjeldsen, Michael A Weber

    Background: Randomized outcome trials have shown the benefit of antihypertensive treatment, but subgroup analyses exploring treatment responses in relation to patient characteristics are usually based on single factors rather than comprehensive patient profiles. We hypothesized that a combination of individual predictors better identifies patients who are more or less likely to achieve blood pressure (BP) control. Methods: To test our hypothesis, we reanalysed the data from the double-blinded VALUE-outcome trial (n=15,313). The patient population was divided into an exploratory cohort (2/3) and a validation cohort (1/3). We constructed composite patient profiles by combining four proven predictors of BP control: age, severity of hypertension, comorbidity and previous treatment status. Logistic regression and Cox proportional hazard models were used to test whether BP control and cardiovascular event rates differed among these profiles, and whether profiling conferred additional predictive information beyond the individual factors alone. Results: BP control rates differed significantly between patient profiles, regardless of treatment (likelihood ratio test, p<0.001). Results from the exploratory cohort were reproducible in the validation cohort. Profiling predicted BP control significantly better than any individual factor (p<0.001 for all comparisons). In addition, there were significant associations between profiles and the incidence of cardiovascular events. Adverse events, however, were not related to profiles. Conclusions: We conclude that composite patient profiles may predict BP responses to antihypertensive treatment more accurately than single factors. These findings may help to better individualize antihypertensive therapy.

  • Open Access

    On-treatment systolic blood pressure and preserved kidney function in hypertensive patients with proteinuria. The VALUE Trial

    by Eirik Olsen, Julian E. Mariampillai, Roland E. Schmieder, Kenneth Jamerson, Camilla L. Søraas, Giuseppe Mancia, Maria H. Mehlum, Knut Liestøl, Anne C. K. Larstorp, Lene V. Halvorsen, et al.

    We investigated on-treatment systolic BP (SBP) with proteinuria both at without proteinuria the relation between lower SBP and WKF was not significant (p = 0.23) at with proteinuria and ESKD from 3.5% (Q1) to 1.6% (Q2) (p = 0.13), 0.7% (Q3) (p = 0.027) and 0.1% in Q4 (p = 0.009). In the patients without proteinuria neither WKF nor ESKD showed statistically significant changes between SBP quartiles. Our data suggest that, compared to SBP ≥ 140 mmHg, on-treatment SBP <130 and 130-139 mmHg was strongly related to nephroprotection in hypertensive patients with proteinuria.


  • Open Access

    Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients

    by Eirik Olsen, Camilla L Søraas, Roland E Schmieder, Kenneth Jamerson, Thomas M MacDonald, Giuseppe Mancia, Sondre Heimark, Maria H Mehlum, Knut Liestøl, Anne C K Larstorp, et al.

    BACKGROUND: Protecting the kidneys by lowering systolic blood pressure (SBP) in hypertensive patients is not unequivocally settled. We tested the hypothesis that achieving lower average SBP in middle-aged and older high-risk hypertensive patients with and without type-2 diabetes mellitus through several years would clarify kidney protection. METHODS: We analyzed patients 50–80 years with no cardiovascular events during the first 6 months of drug up-titration after randomization to valsartan or amlodipine, and with 3 or more visits onwards with standardized BP measurements. Adjusted Cox analyzes compared worsened kidney function defined as a 50% rise in se-creatinine on a minimum of two occasions at least 4 weeks apart or end-stage kidney disease (ESKD) in achieved SBP quartiles and in patients who achieved SBP < 130 and 130–139 mmHg with patients whose SBP remained ≥140 mmHg. RESULTS: A total of 13,803 patients were investigated of whom 4,655 had DM. Patients with DM had less worsened kidney function at SBP 130–139 mmHg (HR = 0.524, 95% CIs 0.375–0.733, n = 1849, P < 0.001) and at SBP < 130 mmHg (HR = 0.538, CIs 0.316-0.915, n = 674, P = 0.022) compared with patients at ≥ 140 mmHg. They also had less ESKD at SBP 130-139 mmHg (HR = 0.442, CIs 0.196–1.000, P = 0.050) with a similar trend at SBP < 130 mmHg and in quartile analysis with only 1 ESKD in the lowest quartile. Findings in patients without DM (n = 9,148) were similar to DM. CONCLUSIONS: In high-risk hypertensive patients aged 50–80 years, with and without DM, targeting SBP of 130–139 mmHg confers kidney protection with possible further benefit at the lower target of SBP < 130 mmHg. Clinical trials registration: Trial Number NCT06395194, www.clinicaltrials.gov.


  • Insights from the VALUE Trial: Achieving blood pressure targets for renal protection

    by Eirik Olsen, Camilla L. Søraas, Julian E. Mariampillai, Sverre E. Kjeldsen, Anne C.K. Larstorp, Morten Rostrup


  • Open Access

    Characteristics of adherent and non-adherent patients with hypertension in a Norwegian cross-sectional study

    by Eirik Olsen, Lene V. Halvorsen, Stine Rognstad, Arleen Aune, Karl Marius Brobak, Ola Undrum Bergland, Vibeke N. Kjær, Knut Liestøl, Marit D. Solbu, Rune Mo, et al.

    Aim: Non-adherence is an important cause of uncontrolled hypertension. We investigated the prevalence of non-adherence to antihypertensive medications by serum drug concentration measurements in a cohort of Norwegian patients from the general population treated for hypertension. We also identified characteristics associated with non-adherence. Methods: Patients with hypertension using ≥ 2 antihypertensive agents were invited to participate in this national study performed in a semi-blinded fashion. Exclusion criteria were dementia, substance or alcohol abuse, pregnancy, terminal illnesses, poor Norwegian language skills, or severe kidney failure [glomerular filtration rate (GFR) < 30 mL/min/1.73 m2]. All patients had their antihypertensive drugs in serum analyzed by ultra-high-pressure liquid chromatography-tandem mass spectrometry to identify their adherence to the 23 most used antihypertensive agents. Additionally, they underwent a thorough standardized interview, office blood pressure (BP), and 24-hour ambulatory BP measurement. Results: n = 1,151 patients were investigated for BP control and drug adherence. Among these, n = 79 (6.9%) patients were identified as non-adherent, and n = 1,072 (93.1%) patients were identified as adherent by pharmacologists who reviewed the drug concentrations in blood in relation to self-reported prescribed medications. We found the non-adherent patients to be younger (56.9 vs. 63.7 years, p < 0.001), with higher systolic and diastolic office BP (150.4/91.4 vs. 143.2/82.0 mmHg, p < 0.01) and less likely to be of European ethnicity (82.9% vs. 95.8%, p < 0.001). Factors associated with non-adherence in logistic regression analysis were age, number of antihypertensive pills, non-European ethnicity, and inversely the use of angiotensin receptor blockers. Conclusions: We found fewer non-adherent patients than expected in patients on ≥ 2 antihypertensive drugs compared to previous investigations of patients on ≥ 3 antihypertensive drugs. We believe that selection at inclusion or possibly a higher confidence in physicians’ authority may be of importance. Adherence was significantly and negatively related to younger age, non-European ethnicity, and increasing number of prescribed antihypertensive pills, and positively to the type of prescribed medication, especially angiotensin receptor blocker (www.ClinicalTrials.gov identifier: NCT03209154).


  • Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial

    by Mislav Vrsalovic, Sondre Heimark, Camilla L. Søraas, Maria H. Mehlum, Sverre E. Kjeldsen, Giuseppe Mancia, Stevo Julius, Michael A. Weber

    BACKGROUND: Systolic blood pressure (BP) is a key predictor of cardiovascular events, but patients with peripheral artery disease (PAD) are rarely included in hypertension trials. The VALUE trial (Valsartan Antihypertensive Long-Term Use Evaluation) investigated the long-term effects of valsartan- or amlodipine-based treatments on cardiovascular outcomes in patients with hypertension with a high cardiovascular risk. The aim of this subanalysis was to clarify the relationship between achieved BP on treatment and cardiovascular outcomes in patients with hypertension with PAD. METHODS: Patients were followed for 4 to 6 years, and BP was measured regularly. The primary end point was time to the first major adverse cardiovascular event, including myocardial infarction, stroke, cardiovascular death, and heart failure requiring hospitalization. Statistical analyses were performed using Cox regression, adjusting for various baseline covariates. RESULTS: Of the 13 803 participants, 1898 (13.8%) had PAD. During a median follow-up of 4.5 years, patients with PAD had a 23% increased risk of major adverse cardiovascular events compared with patients without PAD. Patients with an achieved systolic BP P =0.037; 0.85 [95% CI, 0.74–0.97]; P =0.016, respectively). Additionally, systolic BP P =0.034). The incidence of the primary outcome did not differ between antihypertensive treatment regimens ( P =0.365). CONCLUSIONS: Our results indicate that more intensive BP control is associated with a reduction in cardiovascular morbidity and mortality in patients with hypertensive PAD.


  • Open Access

    Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg

    by Sondre Heimark, Maria H. Mehlum, Giuseppe Mancia, Camilla L. Søraas, Knut Liestøl, Kristian Wachtell, Anne C. Larstorp, Morten Rostrup, Julian E. Mariampillai, Sverre E. Kjeldsen, et al.

    BACKGROUND: Approximately 40% of people with hypertension have left ventricular hypertrophy (LVH) detected by ECG or echocardiography. Because patients with LVH have poor myocardial microcirculation, they may be too sensitive to lowering systolic blood pressure (SBP) too much due to a lack of myocardial perfusion pressure. We aimed to investigate whether the average achieved SBP P =0.032) and all-cause mortality (hazard ratio, 1.74 [95% CIs, 1.17–2.60]; P =0.007), and SBP <130 mm Hg was not associated with a reduction in any end point. CONCLUSIONS: Our findings may be seen as a signal that caution is warranted when treating middle-aged and older patients with electrocardiographic or echocardiographic LVH to SBP <130 mm Hg.


  • Open Access

    Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial

    by Sonja H Brunvoll, Anders B Nygaard, Merete Ellingjord-Dale, Petter Holland, Mette Stausland Istre, Karl Trygve Kalleberg, Camilla L Søraas, Kirsten B Holven, Stine M Ulven, Anette Hjartåker, et al.

    Objective To determine if daily supplementation with cod liver oil, a low dose vitamin D supplement, in winter, prevents SARS-CoV-2 infection, serious covid-19, or other acute respiratory infections in adults in Norway. Design Quadruple blinded, randomised placebo controlled trial. Setting Norway, 10 November 2020 to 2 June 2021. Participants 34 601 adults (aged 18-75 years), not taking daily vitamin D supplements. Intervention 5 mL/day of cod liver oil (10 µg of vitamin D, n=17 278) or placebo (n=17 323) for up to six months. Main outcome measures Four co-primary endpoints were predefined: the first was a positive SARS-CoV-2 test result determined by reverse transcriptase-quantitative polymerase chain reaction and the second was serious covid-19, defined as self-reported dyspnoea, admission to hospital, or death. Other acute respiratory infections were indicated by the third and fourth co-primary endpoints: a negative SARS-CoV-2 test result and self-reported symptoms. Side effects related to the supplementation were self-reported. The fallback method was used to handle multiple comparisons. Results Supplementation with cod liver oil was not associated with a reduced risk of any of the co-primary endpoints. Participants took the supplement (cod liver oil or placebo) for a median of 164 days, and 227 (1.31%) participants in the cod liver oil group and 228 (1.32%) participants in the placebo group had a positive SARS-CoV-2 test result (relative risk 1.00, multiple comparison adjusted confidence interval 0.82 to 1.22). Serious covid-19 was identified in 121 (0.70%) participants in the cod liver oil group and in 101 (0.58%) participants in the placebo group (1.20, 0.87 to 1.65). 8546 (49.46%) and 8565 (49.44%) participants in the cod liver oil and placebo groups, respectively, had ≥1 negative SARS-CoV-2 test results (1.00, 0.97 to 1.04). 3964 (22.94%) and 3834 (22.13%) participants in the cod liver oil and placebo groups, respectively, reported ≥1 acute respiratory infections (1.04, 0.97 to 1.11). Only low grade side effects were reported in the cod liver oil and placebo groups. Conclusion Supplementation with cod liver oil in the winter did not reduce the incidence of SARS-CoV-2 infection, serious covid-19, or other acute respiratory infections compared with placebo. Trial registration ClinicalTrials.gov NCT04609423.


  • Open Access

    Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study

    by Arne Søraas, Karl Trygve Kalleberg, John Arne Dahl, Camilla Lund Søraas, Tor Åge Myklebust, Eyvind Axelsen, Andreas Lind, Roar Bævre-Jensen, Silje Bakken Jørgensen, Mette S. Istre, et al.

    Long-COVID-19 is a proposed syndrome negatively affecting the health of COVID-19 patients. We present data on self-rated health three to eight months after laboratory confirmed COVID-19 disease compared to a control group of SARS-CoV-2 negative patients. We followed a cohort of 8786 non-hospitalized patients who were invited after SARS-CoV-2 testing between February 1 and April 15, 2020 (794 positive, 7229 negative). Participants answered online surveys at baseline and follow-up including questions on demographics, symptoms, risk factors for SARS-CoV-2, and self-rated health compared to one year ago. Determinants for a worsening of self-rated health as compared to one year ago among the SARS-CoV-2 positive group were analyzed using multivariate logistic regression and also compared to the population norm. The follow-up questionnaire was completed by 85% of the SARS-CoV-2 positive and 75% of the SARS-CoV-2 negative participants on average 132 days after the SARS-CoV-2 test. At follow-up, 36% of the SARS-CoV-2 positive participants rated their health “somewhat” or “much” worse than one year ago. In contrast, 18% of the SARS-CoV-2 negative participants reported a similar deterioration of health while the population norm is 12%. Sore throat and cough were more frequently reported by the control group at follow-up. Neither gender nor follow-up time was associated with the multivariate odds of worsening of self-reported health compared to one year ago. Age had an inverted-U formed association with a worsening of health while being fit and being a health professional were associated with lower multivariate odds. A significant proportion of non-hospitalized COVID-19 patients, regardless of age, have not returned to their usual health three to eight months after infection.